Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;55(10):2887-92.
doi: 10.1007/s10620-009-1097-5. Epub 2010 Jan 22.

Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study

Aleksandra Sokic-Milutinovic  1 , Miodrag Krstic, Brigita Rozer-Smolovic, Tamara Alempijevic
Affiliations

Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study

Aleksandra Sokic-Milutinovic et al. Dig Dis Sci. 2010 Oct.

Abstract

Aims: We aimed to determine differences in gastroduodenal damage related to the presence of Helicobacter pylori (Hp) in patients starting long-term NSAID therapy. Seventy-one candidates for chronic NSAIDs therapy (33 Hp negative and 38 Hp positive) entered the study and underwent upper GI endoscopy before, and 8 and 16 weeks after, continuous NSAID therapy.

Results: Lanza score increased in both Hp positive and negative patients in the course of NSAID therapy (P < 0.001), being significantly higher in Hp positive than Hp negative (4.31 ± 1.33 vs 3.15 ± 1.95, P < 0.05) after 16 weeks of follow-up. In gastric mucosa, no significant difference in mean Lanza score was observed between the two groups. Duodenal ulcer was diagnosed in 18 (36.8%) Hp positive and 1 (3%) Hp negative patient (P < 0.05).

Conclusions: Hp is more closely related to duodenal than gastric mucosal injury in NSAID users. Risk for duodenal ulcer in Hp-infected individual increases after 4 months of NSAID therapy.

PubMed Disclaimer

References

    1. Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:9-16 - PubMed
    1. Lancet. 1997 Oct 4;350(9083):975-9 - PubMed
    1. Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:65-70 - PubMed
    1. Gut. 2002 Sep;51(3):329-35 - PubMed
    1. Gut. 2001 Sep;49(3):443-53 - PubMed

MeSH terms

Substances